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Abstract: Programmed cell death pathways eliminate infected cells and regulate infection-associated
inflammation during pathogen invasion. Cytomegaloviruses encode several distinct suppressors that
block intrinsic apoptosis, extrinsic apoptosis, and necroptosis, pathways that impact pathogenesis
of this ubiquitous herpesvirus. Here, we expanded the understanding of three cell autonomous
suppression mechanisms on which murine cytomegalovirus relies: (i) M38.5-encoded viral mitochondrial inhibitor of apoptosis (vMIA), a BAX suppressor that functions in concert with M41.1-encoded
viral inhibitor of BAK oligomerization (vIBO), (ii) M36-encoded viral inhibitor of caspase-8 activation (vICA), and (iii) M45-encoded viral inhibitor of RIP/RHIM activation (vIRA). Following
infection of bone marrow-derived macrophages, the virus initially deflected receptor-interacting
protein kinase (RIPK)3-dependent necroptosis, the most potent of the three cell death pathways.
This process remained independent of caspase-8, although suppression of this apoptotic protease enhances necroptosis in most cell types. Second, the virus deflected TNF-mediated extrinsic apoptosis,
a pathway dependent on autocrine TNF production by macrophages that proceeds independently of
mitochondrial death machinery or RIPK3. Third, cytomegalovirus deflected BCL-2 family proteindependent mitochondrial cell death through combined TNF-dependent and -independent signaling
even in the absence of RIPK1, RIPK3, and caspase-8. Furthermore, each of these cell death pathways
dictated a distinct pattern of cytokine and chemokine activation. Therefore, cytomegalovirus employs
sequential, non-redundant suppression strategies to specifically modulate the timing and execution
of necroptosis, extrinsic apoptosis, and intrinsic apoptosis within infected cells to orchestrate virus
control and infection-dependent inflammation. Virus-encoded death suppressors together hold
control over an intricate network that upends host defense and supports pathogenesis in the intact
mammalian host.
Keywords: BCL2 family; mitochondria; serine protease; herpesvirus; apoptosis; extrinsic apoptosis;
intrinsic apoptosis; pyroptosis; necroptosis; inflammation; TNF; IFN; DNA virus; cytomegalovirus;
replication; HCMV; MCMV; cmvPCD; UL36; M36; vICA; M45; vIRA; M38.5; M41.1; vMIA; vIBO
Caspase-8; RIPK1; RIPK3; myeloid cells; macrophages; cell death
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1. Introduction
In the arms race between eukaryotic hosts and pathogens, programmed cell death
(PCD) mechanisms evolved as a network of pathways primarily intended to sustain health
by resisting infection [1–5]. PCD pathways play roles in host defense against intracellular pathogens by eliminating cells before the production of progeny occurs. A primary
form of PCD is apoptosis, a caspase (CASP)-dependent death pathway initiated either by
infection-associated external danger signals (extrinsic) or by intracellular stress sensed via
mitochondria (intrinsic) [5–7]. An alternate form of cell death, necroptosis, unleashes in
the face of virus-encoded CASP inhibitors and has been characterized as a highly potent
host defense pathway known to limit the ability of a pathogen to invade the host [8–10].
Cytomegalovirus (CMV) has evolved to be a ubiquitous, highly successful mammalian
pathogen by employing an array of conserved immunomodulatory strategies that subvert
anti-viral defenses, particularly through the effective suppression of both extrinsic and intrinsic PCD pathways [10–19]. These suppression strategies sustain human (H) and murine
(M) CMV replication in cells and, most importantly, ensure fitness in vivo [10,12–18].
HCMV is a significant pathogen with protean clinical manifestations where pathogenesis depends on viral replication as well as immune cell-driven inflammation [20–27]. The
contribution of PCD suppression to pathogenesis remains poorly understood. Studies in
MCMV have revealed similarities to HCMV in pathogenesis, host-pathogen interactions,
and antiviral host defense mechanisms [10,17,23]. We, and others, have identified distinct,
conserved pathways that mold the inflammatory environment through crosstalk in addition to restricting MCMV replication [28–32]. All known DNA viruses encode inhibitors of
CASP8 [5]. The viral inhibitor of caspase activation (vICA) suppresses innate inflammatory signaling in human or murine cells to sustain MCMV fitness [30,33,34]. Both HCMV
and MCMV also suppress mitochondrial cell death by targeting the B cell lymphoma-2
(BCL2)-associated X protein (BAX) and BCL-2 homologous antagonistic killer (BAK) during
infection [17,31,32,35–38]. Here, we utilized MCMV infection to investigate how combined
BAX and BAK suppression by the MCMV-encoded suppressors impact pathogenesis as
well as how mitochondrial signaling interfaces with other PCD pathways.
As cellular stress is conveyed to the mitochondria, monomeric BAX and BAK homooligomerize at the mitochondrial outer membrane (MOM), driving a well-defined PCD
outcome [39–41] where BAX/BAK oligomers drive increased mitochondrial membrane permeability resulting in the release of cytochrome c, reactive oxygen species, and HtrA2/Omi
with a consequent activation of CASP9, Apaf-1, and executioner CASP3 and CASP7 [41–43].
BCL-2 family proteins BID, BIM, and PUMA may act upstream of BAX and BAK [44]. All
large DNA viruses encode suppressors of mitochondrial cell death [45,46]. Mitochondria
also control CASP-independent death pathways [47,48] such as the HtrA2/Omi-dependent
pathways that are suppressed by the viral inhibitor of mitochondrial apoptosis (vMIA) during HCMV replication [13,49]. Related suppressors are encoded by adenovirus E1B [50,51],
vaccinia virus F1L [52], myxoma virus M11L [53,54], and gammaherpesvirus vBCL-2 homologs [55]. Activated BID bridges extrinsic death signaling with BAX/BAK-dependent
mitochondrial cell death, an amplification step that may be crucial in cells where CASP8
levels are too low to directly cleave CASP3 and/or CASP7 [56–58]. This amplification
contributes markedly to extrinsic death signaling through the TNF-TNFR1-CASP8 signaling axis. During HCMV infection, gene product UL37x1-encoded vMIA suppresses
the activation of BAX as well as BAK [16,59]. Thus, vMIA suppresses caspase-dependent
as well as caspase-independent forms of PCD, ensuring cells survive and produce viral
progeny. MCMV encodes two related cell death suppressors: M38.5-encoded vMIA that
targets the BAX [17,36,60,61] and M41.1-encoded viral inhibitor of BAK oligomerization
(vIBO) [32,38,62,63]. Individually, vMIA- or vIBO-deficient MCMV exhibit a modest impact on pathogenesis [31,32,38,61–63], consistent with the target protein specificity and the
known overlap in BAX and BAK function in contrast to the broader function of HCMV
vMIA. Studies with single mutants disrupting vMIA or vIBO function reveal that BAX or
BAK suppression occurs in a cell type-dependent fashion [30–32]. The combined effect of
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vMIA and vIBO on virus fitness, replication, and pathogenesis, as well as crosstalk with
innate cytokine activation remains to be investigated.
Here we showed that combined BAX/BAK suppression by vMIA/vIBO prevents
intrinsic PCD, limits HtrA2/Omi impact, and regulates innate inflammation. vMIA/vIBO
remain essential for sustained MCMV titers in the salivary glands of mice, the tissue
known to mediate horizontal transmission of CMV. Macrophages represent a relevant,
natural setting where MCMV-encoded PCD suppressors show functions that correspond
to behavior in infected hosts [30]. Macrophages and their monocyte precursors play central
roles during CMV pathogenesis by sustaining viral replication to support reservoirs that
underly life-long persistence and latency [64–71]. We showed that MCMV faces receptor
interacting protein (RIP) kinase (RIPK)3-dependent necroptosis within ~6 to 9 h, TNFR1dependent CASP8 activation within ~12 h, and mitochondrial cell death within ~24 h of
infection. Thus, PCD pathways are temporally staged and the suppression of each PCD
pathway proceeds independently based on studies that rely on mutant macrophages that
lack specific cell death components. MCMV gene products, M45-encoded viral inhibitor
of RHIM activation (vIRA), M36-encoded vICA, and M38.5/M41.1 encoded vMIA and
vIBO work in a concerted manner during infection with each suppressor playing a largely
non-redundant role in sustaining viability, facilitating virus replication, and orchestrating
infection-associated inflammation. vMIA/vIBO also suppresses the amplification of TNF
signaling via mitochondria and likely underlies observations showing M36 mutant MCMV
does not activate this sub-pathway [72]. The interfacing of the mitochondrial suppressors
with the TNF signaling brings to light new insights regarding the role of this inflammatory
cytokine in CMV biology, revealing impacts on replication in a variety of cell types as well
as pathogenesis in vivo [73–76].
Given that vMIA/vIBO function plays out independently of extrinsic apoptotic or
necroptotic players, MCMV employs sequential, specific suppression mechanisms with
non-overlapping functions to establish a protective shield against host immunity. This
prevents viral clearance and ensures fitness. Our work sheds light on the potential for
targeting the CMV-encoded PCD suppressors as well as the associated host pathways as
intervention strategies to reduce pathogen load and disease pathogenesis.
2. Materials and Methods
2.1. Cell Culture and Reagents
3T3-SA fibroblasts (ATCC CCL-92), SVEC4-10 endothelial cells (ATCC CRL-2181),
and 293-T cells were maintained at 37 ◦ C with 5% CO2 in Dulbecco’s modified Eagle
medium (DMEM) containing 4.5 g/mL glucose, 1 mM sodium pyruvate, 10% fetal bovine
serum (Atlanta Biologicals, Oakwood, GA, USA), 2 mM L-glutamine, 100 U/mL penicillin,
and 100 U/mL streptomycin (Invitrogen, Waltham, MA, USA). BMDM were generated
as described previously [72]. Briefly, flushed marrows from tibias and femurs of 8- to
12-week-old mice were cultured for 7 days in DMEM containing 4.5 g/mL glucose (10-013
CV, Corning, Charlotte, NC, USA), 10% fetal bovine serum (F2442, Sigma-Aldrich, St. Louis,
MO, USA), and 2 mM L-glutamine (MT 25005CI, ThermoFisher Scientific, Marietta, GA,
USA) supplemented with 100 units/mL penicillin and 100 units/mL streptomycin (MT
3002CI, Thermo Fisher Scientific, Waltham, MA, USA). For BMDM culture, this complete
DMEM medium had a final 20% fetal bovine serum and 20% filtered L929-conditioned
medium (as a source of macrophage colony-stimulating factor). Cells were harvested from
C57BL/6 (referred to as WT), Ripk3−/− Casp8−/− , RIPK3−/− , Ripk1−/− Casp8−/− Ripk3−/− ,
Ripk1K45A/K45A , Ripk3K50A/K50A , Asc−/− , Aim2−/− , Ifnar1−/− , Ifngr−/− , and Gsdmd−/− [77],
Zbp−/− [78], Bak−/− Baxfl/fl (also referred to as Baxtm2Sjk Bak1tm1Thsn/J ) [38], Bid−/− , Bim−/− ,
Puma−/− , Bid−/− Bim−/− Puma−/− [79], Bax−/− Bak−/− [80], and Bok−/− [81] mice. BAX
knockdown in Bak−/− Baxfl/fl BMDM cells was achieved by infection with lentivirus expressing Cre recombinase. Lentiviral stocks were generated by transfecting 293-T cells
with LV-Cre or control LV-GFP (Addgene, Watertown, MA, USA) along with packaging
plasmids psPAX2 and VSV-G [82]. Supernatant containing the lentiviral particles was
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collected 24, 48, and 72 h post transfection, filtered through a 0.45-micron filter, subjected
to a flash-freeze, and stored at −80 ◦ C until use. WT and Bak−/− Baxfl/fl BMDM cells were
thawed and cultured in the lentiviral supernatant collected at 24 h post transfection for
8 h. Medium was replaced and the BMDM cells were allowed to recover overnight. This
process was repeated twice using supernatant collected at 48 and 72 h post transfection.
Following infection with lentiviral particles, BMDM cells were allowed to rest for two
days before seeding. For TNF treatment of cells, 25 ng/mL of recombinant murine TNF
(315-01A, Peprotech Inc, Cranbury, NJ, USA) was added 1 hpi with viruses. All cells were
maintained at 37 ◦ C in a humidified 5% CO2 incubator.
2.2. BAC Mutagenesis and Recombinant Viruses
Escherichia coli strain DH10B harboring plasmid pSIM6 encoding the λ red recombineering functions [83] and MCMV strain K181-BAC [84] were utilized to introduce
insertion mutations in the viral genome. To generate a virus lacking both of these mitochondrial cell death suppressors, a vIBO-deficient virus that was generated and characterized previously, m41.1.∆Start-BAC [38], was employed. A selection/counterselection
cassette, KanR /SacB, was inserted into M41.1.∆Start-BAC within the m38.5 reading frame
and upstream of overlapping M38. This virus was named ∆M38.5/M41.1-BAC, signifying the presence of large insertion disrupting m38.5 and a point mutation in M41.1.
The following primers were used to insert the Kan/SacB cassette: M38.5 Kan/SacBF(50 ccaagcgccccagaggcgaagagcagcgctggtcgttcgcttacaaacccaattcgagctcggtacccgg); M38.5
Kan/SacB-R(50 ggttgtagttgtggaggggacagcgatggagagtgtgcgccgacccttctatcccgggaaaagtgccacc).
A second double mutant virus was generated to confirm the results produced by
∆M38.5/m41.1-BAC and to identify differences that may be due to the insertion cassette disrupting M38.5 as well as neighboring genes. The second double mutant virus,
M38.5.StopFS/M41.1.∆Start-BAC, was also generated from M41.1.∆Start-BAC with the
more efficient En Passant mutagenesis system [85,86]. A point mutation was engineered
into M38.5, creating a stop codon and frame shift mutation just eight amino acids from the
start of the protein. Furthermore, the point mutation created an XbaI restriction site used for
screening and characterization of the mutant virus. The following primers were used to insert this point mutation: M38.5.StopFS-F(50 gcgccccagaggcgaagagcagcgctggtcgttcgcttacaaac
cctctagaagggtcggcgcacaggatgacgacgataagtaggg) and M38.5.StopFS-R(50 gtagttgtggaggggaca
gcgatggagagtgtgcgccgacccttctagagggtttgtaagcgaaccaaccaattaaccaattctgattag). Finally, a single M38.5 mutant virus, M38.5.StopFS-BAC, was generated from the parental K181-BAC
with the same point mutations using the primers described above.
All BAC-derived clones were screened by sequencing PCR products over the M41/M41.1
locus as previously described [38] as well as over the M38.5 locus. The following primers
were used to amplify and screen the M38.5 locus: M38.5-F(50 gcagaagtcacgtcggatccag);
m38.5-R(50 ggctgctacgagaacgtgac). Furthermore, BAC-derived full-length clones were analyzed by RFLP with five restriction enzymes to ensure the integrity of the viral genome.
Following genetic characterization, mutant and parental viruses were reconstituted and
plaque-purified as previously described [38]. Growth curves and viral yields were performed by infecting cells in a 48-well plate in 0.25 mL of viral inoculum at the indicated
multiplicity of infection (MOI) for 1 h at 37 ◦ C with 5% CO2 . Following adsorption, the
inoculum was replaced with complete DMEM. Samples were harvested at the indicated
times, sonicated, and titered by plaque assay on 3T3-SA fibroblasts.
2.3. Mice, Infections, and Organ Harvests
BALB/c, B6 × 129 P2, and C57BL6/J mice were obtained from Jackson Laboratory
(Bar Harbor, ME USA). B6 × 129-Baxtm2Sjk Bak1tm1Thsn/J (also referred to as Bak−/− Baxfl/fl )
were obtained and used as previously described [38]. Casp8−/− RIPK3−/− were bred and
maintained as previously described [87]. Six-week-old BALB/c mice were infected via the
intraperitoneal (IP) route of inoculation with 2 × 105 PFU of tissue culture-derived virus.
Other strains of mice (6–18 weeks old) were infected via the IP route or via footpad route
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with 1 × 106 PFU or 5 × 106 PFU of virus respectively. At the time of sacrifice, organs were
placed in 1 mL of complete DMEM, disrupted by sonication, and virus titer was determined
by plaque assay as described [30]. IE1 positive cells were identified as described [30].
2.4. Cell Viability Assay
At the indicated times, cell viability was determined by measuring the ATP levels using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega Corporation, Madison,
WI, USA) according to manufacturer’s protocol. Cells (~50,000 cells/well) were seeded
into 96-well plates in triplicate. Approximately 18 h post seeding, medium was replaced
with 100 µL of virus inoculum containing 10 PFU/cell (MOI = 10). At 24 hpi, and DNA
fragmentation was visualized by the DeadEnd Fluorometric TUNEL System (Promega
Corporation, Madison, WI, USA). Cells (60,000/well) were seeded into 48-well plates in
triplicate. Approximately 18 h post seeding, cells were infected at MOI = 10. The number
of cells with detectable fragmented DNA were expressed as a percent of cells expressing
IE1. To assess cell morphology, cells were plated in 48-well plates as indicated above
and infected with virus at MOI = 20 at 18 h post plating. Phase-contrast microscopy was
performed 24 hpi. To assess the inclusion of cell permeable SYTOX, Green dye (S7020,
Invitrogen, Waltham, MA, USA) uptake was used in real time using an IncuCyte instrument (Essen BioScience, Ann Arbor, MI, USA) as described [82]. BMDM were plated at
5 × 104 cells per well in 24-well tissue culture plates. Cells were infected as described
above at MOI = 10.
2.5. Immunoblot Analysis
To detect BAX quantities, cells were lysed in 50 mM Tris (pH 7.0), 2% sodium dodecyl
sulfate (SDS), 5% β-mercaptoethanol, and 2.75% sucrose. Cell lysates were boiled for
5 min, separated by SDS-polyacrylamide gel electrophoresis (15% gel), transferred to
Immobilon-P PVDF membranes (Millipore Sigma, Burlington, MA, USA), and subjected to
immunoblot analysis. For identification of CASP activation patterns, infected cells were
harvested at 24 hpi and evaluated as described previously [29]. Briefly, 5 × 106 BMDM were
plated in a 10-cm tissue culture dish. Twenty-four hours post-plating, cells were infected
with the virus. Lysates were harvested utilizing 1000 µL of ice-cold Triton-X lysis buffer
supplemented with protease and phosphatase inhibitors for 30 min. Ultracentrifuged
(150,000 rpm at 4 ◦ C for 20 min) lysates were separated from Triton-X insoluble pellets.
Pellets were sonicated for 10 s at 20 watts in 150 µL of disruption buffer (50 mM Tris pH
6.8, 5% β-mercaptoethanol, 2.75% [w/v] sucrose and 2% [w/v] SDS). Given the comparable
sizes of the caspases (for both total and cleaved forms), individual immunoblotting was
performed for each caspase. Loading control actin was detected for each caspase blot
individually. Antibodies for immunoblots: anti-BAX (BioLegend, SanDiego, CA, USA;
clone 5B7 (currently discontinued by manufacturer)); rabbit anti-CASP9 (9504), rabbit
anti-cleaved CASP8 (8592), rabbit anti-cleaved CASP7 (8438), rabbit anti-cleaved CASP3
(9661), (all from Cell Signaling Technology, Denvers, MA, USA), and mouse anti-β-actin
(A2228, Sigma-Aldrich, St. Louis, MO, USA).
2.6. Cytokine Array
Released cytokines and chemokines were detected by cytokine array (Cytokine Array
Panel A, ARY006, R&D Systems, Minneapolis, MN, USA). Supernatants were collected
from cultures of WT BMDM infected with MCMV (K181 or mutant) for 24 h. Following
centrifugation at 500 g for 5 min at 4 ◦ C, cell-free supernatants were pooled from two independent experiments for each condition. Array strips were exposed to chemiluminescent
chemicals (provided with the kit) and raw images were developed on X-ray film. Films
were analyzed using Adobe Photoshop 8 to generate pixel intensity of dots corresponding
to individual cytokines as well as reference dots. Pixel intensities of control dots were
averaged for each array strip. For comparing four array strips (heat map in Figure 3),
reference spots were normalized across the dot blots.
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2.7. Statistics
All statistical analyses were performed using GraphPad Prism 8 Software (GraphPad
Software Inc. La Jolla, CA, USA). Two groups of data were compared for significance using
non-parametric, Wilcoxon matched-pairs signed rank test; three or more groups of data
were compared using ANOVA. All graphs show standard error and mean for datasets,
except viral titers in organs where mean is indicated for each data set. p-values (p) of <0.05
were considered significant and indicated with * <0.05, ** <0.01, *** < 0.001, **** <0.0001.
2.8. Software
Chemiluminescent images of immunoblots were captured using the Kwik Quant
system (Kindle Biosciences, Greenwich, CT, USA) and analyzed on Adobe Photoshop
8 (Adobe Corporation Inc., San Jose, CA, USA). All cell death as well as ELISA data
were assembled using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and
graphed using GraphPad Prism 8 (GraphPad Software Inc. San Diego, CA, USA). For
cytokine array, pixel intensities were determined using Adobe Photoshop 8. All figures
were assembled using Adobe Illustrator 8. Software Inc. San Diego, CA, USA). Model
cartoons were constructed using BioRender software (BioRender, Toronto, ON, Canada).
2.9. Data Availability
Further information and requests for resources and reagents should be directed to
and will be fulfilled by mocarski@emory.edu and pratyusha.mandal@emory.edu. All data
are included in manuscript. All raw files are available upon request. This manuscript
generated a new MCMV mutant (∆M38.5/M41.1 double mutant virus) that is available
upon request. All reagents utilized are described in detail in these methods.
2.10. Study Approval
All experiments were conducted with approval (4 February 2019, Proto 201700351)
from the Emory University Biohazard, Chemical Hazard Review and Animal Use (IACUC)
Committees.
3. Results
3.1. M38.5-Encoded vMIA and M41.1-Encoded vIBO Support Viral Fitness
To determine the impact of combined BAX/BAK suppression by M38.5-encoded vMIA
and M41.1-encoded vIBO, we compared the replication of mutant viruses to parental K181
(Figure 1A–C). The genomic integrity of double mutants and control viruses were confirmed
by direct evaluation (Figure S1A), as previously shown for single mutant viruses [29,30,38].
MCMV was shed in saliva mediates horizontal transmission [88], so viral load in these
glands may therefore be considered an indicator of viral fitness. MCMV detection in
salivary glands requires entry followed by replication in cells at the origin of infection,
myeloid-cell mediated dissemination to different tissues including the salivary glands, and
ultimate replication salivary glands [88–93]. Virus-encoded modulators of adaptive and
innate immunity (including cell death suppressors) suppress host defense to influence
infection at different stages in dissemination [30,93,94]. We determined the titers of mutant
viruses described in the salivary glands of BALB/c mice inoculated intraperitoneally and
C57BL6/J mice inoculated via footpad at 14 days post infection (dpi) (Figure 1B,C). At
14 dpi, vMIA/vIBO-deficient viruses (∆M38.5/M41.1 and M38.5.StopFS/M41.1.∆Start)
showed titers that averaged ~1000-fold lower than K181 in the salivary glands of highly
susceptible BALB/c mice (Figure 1B). Viral titers were markedly more variable and lower
in most animals than observed with single mutant viruses (M38.5.StopFS or M41.1.∆Start),
which exhibited a modest compromise compared with K181 [30,38]. The variability of
double mutant viruses contrasts the invariant titers of K181, or single mutants, reflecting the
importance of BAX and BAK suppression to sustaining MCMV fitness. All mutants (single
or double) remained severely compromised when titers were assessed in salivary glands of
C57BL6/J mice following footpad inoculation (Figure 1C). Together, these observations
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revealed that the vMIA/vIBO double mutant MCMV is attenuated for dissemination
to or
8 of 25
replication in salivary glands, highlighting the importance of BAX/BAK suppression for
viral fitness in vivo.

Figure 1. ∆M38.5/M41.1 mutant MCMV is attenuated for replication in vivo in macrophages. (A) Diagrammatic represenFigure 1. ∆M38.5/M41.1 mutant MCMV is attenuated for replication in vivo in macrophages. (A)
tation of the mutations introduced into M38.5 (vMIA) and M41.1 (vIBO). (B,C) Titer of parental MCMV (K181) or indicated
Diagrammatic representation of the mutations introduced into M38.5 (vMIA) and M41.1 (vIBO).
mutant viruses in salivary glands from 6-week-old BALB/c (B) or C57BL6/J (C) mice at 14 dpi following inoculation
(B,C) Titer of parental MCMV (K181) or indicated mutant viruses in salivary glands from 6-weekwith 2 × 105 PFU intraperitoneally (B) or 5 × 106 PFU subcutaneously into a footpad (C). Each symbol represents the
old BALB/c (B) or C57BL6/J (C) mice at 14 dpi following inoculation with 2 × 105 PFU intraperitonetiter obtained from a single mouse. Datasets are compared using one-way ANOVA and the mean for each dataset is
ally (B) or 5 × 106 PFU subcutaneously into a footpad (C). Each symbol represents the titer obtained
indicated. (D–F) Replication in C57BL6/J wild type (WT) murine BMDM infected at multiplicity of infection (MOI) of
from a single mouse. Datasets are compared using one-way ANOVA and the mean for each dataset
0.5 (D); 3T3-SA fibroblasts (E) and SVEC4-10 endothelial cells (F) infected at MOI of 0.3. Data shown are pooled results
is indicated. (D–F) Replication in C57BL6/J wild type (WT) murine BMDM infected at multiplicity
from three experiments for each setting and the dotted line indicates the limit of detection for each group. Each data set is
of infection (MOI) of 0.5 (D); 3T3-SA fibroblasts (E) and SVEC4-10 endothelial cells (F) infected at
compared using one-way ANOVA. (G) Replication of K181 or ∆M38.5/M41.1 virus in WT and Htra2/Omi−/− BMDM at
MOI of 0.3. Data shown are pooled results from three experiments for each setting and the dotted
5 dpi following infection at an MOI = 0.5 (left panel) or 5 (right panel). For each panel, data shown are pooled results from
line indicates the limit of detection for each group. Each data set is compared using one-way
at least three experiments. Horizontal lines indicate data compared by Wilcoxon matched-pairs signed
rank test. For panels
ANOVA. (G) Replication of K181 or ∆M38.5/M41.1 virus in WT and Htra2/Omi-/- BMDM at 5 dpi
(D–G), error bars indicate the standard error and mean for each dataset. * is p < 0.05; ** is p < 0.01; **** is p < 0.0001, n.s. is
following infection at an MOI = 0.5 (left panel) or 5 (right panel). For each panel, data shown are
non-significant.
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suppressed, we evaluated the replication of double-deficient viruses in cultured pri-

mary macrophages, and immortalized fibroblasts as well as endothelial cells, all of which
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∆M38.5/M41.1
and
M38.5.StopFS/M41.1.∆Start
vMIA suppresses BAX/BAK-dependent mitochondrial apoptosis, as well as mitochon- viruses
showed severe attenuation in BMDM from wild type (WT) C57BL/6J mice (Figure 1D), a
drial serine protease HtrA2/Omi-dependent death [13]. HtrA2/Omi terminates HCMV infection by inducing CMV-dependent PCD (cmvPCD), which is unleashed earlier by the
vMIA-deficient virus [13]. To determine how mitochondrial HtrA2/Omi interfaces with
MCMV vMIA and vIBO or its function during MCMV infection of macrophages, we infected WT or Htra2/Omi-/- BMDM with K181 or ∆M38.5/M41.1 at two different MOIs (0.5
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pattern that was confirmed for ∆M38.5/M41.1 over a nine-day time course (Figure S1B).
Double-mutant virus did not increase in titer over this time course. Surprisingly, the infection of ∆M38.5/M41.1 in BMDM exhibited reduced IE1+ cells over MOI range from 0.626
through 10 (Figure S1C) at 24 h post infection (hpi), even though no defect in IE1 expression
was observed for either M38.5 or M41.1 single-mutant viruses [31,32]. Importantly, the
M38.5/M41.1 double-mutant viruses were constructed utilizing the original K181 background strain (Figure 1A) that displays no defect in entry for myeloid cells, unlike other
pSM3fr-derived MCMV [95]. The reason vMIA/vIBO mutant MCMV shows this defect
will require further investigation. Immortal 3T3-SA fibroblasts exhibited modestly lower
vMIA/vIBO mutant viral titers at 24 through 72 hpi even though titers increased by 5 dpi
to match K181 (Figures 1E and S1D). SVEC4-10 cells exhibited comparable levels of K181
and mutant virus replication (Figures 1F and S1E). Thus, in culture settings, mitochondrial suppression by vMIA and vIBO contributes most dramatically to viral replication in
macrophages.
3.2. HtrA2/Omi Limits MCMV Replication in Macrophages
The HCMV vMIA-deficient virus has been studied in human fibroblasts, where vMIA
suppresses BAX/BAK-dependent mitochondrial apoptosis, as well as mitochondrial serine
protease HtrA2/Omi-dependent death [13]. HtrA2/Omi terminates HCMV infection
by inducing CMV-dependent PCD (cmvPCD), which is unleashed earlier by the vMIAdeficient virus [13]. To determine how mitochondrial HtrA2/Omi interfaces with MCMV
vMIA and vIBO or its function during MCMV infection of macrophages, we infected WT
or Htra2/Omi−/− BMDM with K181 or ∆M38.5/M41.1 at two different MOIs (0.5 or 5;
Figure 1G). K181 titers were ~50- to 100-fold higher in Htra2/Omi−/− BMDM compared
with WT cells, indicating that this serine protease restricts MCMV infection as it does
HCMV infection [13]. The elaboration of necroptotic, extrinsic apoptotic and mitochondrial
death suppressors (vIRA, vICA, and vMIA/vIBO respectively) failed to completely prevent
HtrA2/Omi-induced restriction of MCMV replication. The vMIA/vIBO double deficient
virus exhibited 5 to 10-fold higher titer in Htra2/Omi−/− BMDM, even though the mutant
virus remained severely attenuated in both WT and Htra2/Omi−/− cells. Thus, HtrA2/Omi
contributes to but is not the primary host effector driving attenuation of the vMIA/vIBO
double-deficient virus. During MCMV infection of macrophages, the combined action of
vMIA/vIBO suppress mitochondrial signaling, including HtrA2/Omi, to benefit sustained
virus replication.
3.3. vMIA and vIBO Suppress BAX/BAK-Dependent Cell Death
In BMDM, the replication defect of ∆M38.5/M41.1 mutant virus became evident by
72 hpi (Figure S1B). In line with these observations, the vMIA/vIBO double-deficient
MCMV sensitized macrophages to loss of viability when compared with K181 infection by
48 hpi (Figure 2A). In ∆M38.5/M41.1 infection settings, a significantly elevated proportion
of IE1(+) cells exhibited DNA fragmentation by TUNEL assay when compared with K181
infection at 24 and 48 hpi (Figure 2B). Both infection settings retained a comparable proportion of IE1(+) cells without DNA fragmentation. At 24 hpi with ∆M38.5/M41.1, ~3–5% of
IE1(−) cells exhibited DNA fragmentation in comparison with ~0.5–1% of K181 infected
cells. Thus, the combined effects of vMIA/vIBO contribute to maintaining nuclear integrity during infection. Viability appeared to be rescued, albeit modestly in Bax−/− Bak−/−
but not Baxfl/fl Bak−/− BMDM (Figure 2C), suggesting that combined BAX and BAK suppresses MCMV-induced death of macrophages. Cell morphology assessed at 24 hpi by
phase contrast microscopy revealed apoptotic morphology with cellular blebbing during ∆M38.5/M41.1 infection (Figure 2D). Therefore, vMIA/vIBO suppression protects
macrophages from BAX/BAK-mediated apoptotic death.
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Figure 2. M38.5 and M41.1 suppress BAX- and BAK-dependent BMDM viability. (A) Viability of WT BMDM infected with
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Cre-recombinase-mediated knockdown of Bax, reduced BAX protein expression in
Baxfl/fl Bak−/− , BMDM, and rescued replication of both double-mutant viruses, confirming
that vMIA/vIBO-mediated suppression of BAX/BAK prevents cell death and facilities replication (Figures 2E and S2A). Rescue of replication was partial potentially due to incomplete
elimination of BAX. Thus, both the viability and replication of ∆M38.5/M41.1 viruses were
rescued by combined downregulation of BAX and BAK. Noteworthy, levels of cell death in
WT, Baxfl/fl Bak−/− , Bax−/− Bak−/− , or HtrA2/Omi−/− cells infected with K181 all appeared
similar. However, Baxfl/fl Bak−/− BMDM treated with LV-cre exhibited modestly increased
K181 replication levels (Figure 2E). This pattern of rescue of viability in Bax−/− Bak−/−
cells raises the possibility that factors not evident in these assays may contribute to the
death initiated by vMIA/vIBO double-deficient MCMV. Given the recognized crucial
functions of BID, BIM, PUMA, and BOK in activating BAX/BAK-dependent cell death,
we assessed viability and viral titer in WT compared to Bid−/− Bim−/− Puma−/− as well as
Bid−/− , Bim−/− , Puma−/− , and Bok−/− BMDM during infection with K!81 or ∆M38.5/M41.1
viruses (Figures 2F left panel and S2B–E). These single-mutant cells all exhibited a similar pattern of infection with either virus comparable to WT settings, demonstrating that,
individually, BID, BIM, PUMA, or BOK are dispensable for suppression of ∆vMIA/vIBOdriven, BAX/BAK-mediated PCD (Figure S2B–E). In contrast, Bid−/− Bim−/− Puma−/−
cells exhibited a significant rescue in replication of either double mutant virus whereas
Bim−/− Puma−/− cells showed a modest rescue (Figure 2F left panel). Together with Figure 1,
these observations demonstrate that macrophages rely on mitochondria in responding
to MCMV infection. The following steps occurred: HtrA2/Omi, together with BAX and
BAK, restricts K181 infection even in the presence of vMIA and vIBO without influencing
cell viability. In infected cells (Figure 2F right panel), combined functions of vMIA and
vIBO primarily suppress BID-BIM-PUMA-BAX-BAK-dependent apoptosis and promote
sustained replication.
3.4. vMIA and vIBO Suppress Contributions from TNF Signaling
During MCMV infection of macrophages, vMIA/vIBO suppress BAX/BAK-dependent
mitochondrial death signaling, vICA suppresses TNF-CASP8-dependent apoptosis, and
vIRA suppresses RIPK3-dependent necroptosis such that ∆M38.5/M41.1, ∆M36, and
M45mutRHIM mutant viruses activate BAX/BAK-, TNF-CASP8-, and RIPK3-mediated
pathways, respectively (Figure 3A). Whether these distinct patterns interface with each
other during infection remains unclear. TNF signaling engages adaptor FADD-dependent
CASP8 activation via TNFR1 independently of BID or BAX and BAK [29,73]. vICA suppresses CASP8 activation to avoid TNFR1-FADD-CASP8-dependent apoptosis and sustain
fitness in vivo [29,30,73]. This TNF-dependent signaling is known to be active in control
over HCMV replication as well as MCMV pathogenesis in vivo [74–76]. Currently, there is
no understanding of how TNF contributes in the vMIA/vIBO suppression axis. WT and
Tnfr1−/− BMDM were infected with K181, ∆M38.5/M41.1, necroptotic M45mutRHIM, or
apoptotic ∆M36 virus for 24 or 48 h (Figure 3B). Remarkably, knockout cells completely resisted ∆M38.5/M41.1-induced cell death at 24 hpi, but became as susceptible as WT BMDM
by 48 hpi, indicating that vMIA and vIBO suppressed an early contribution from TNF signaling to cell death. The addition of extraneous TNF to BMDM did not alter susceptibility
of cells to mutant virus infection (Figure 3C). These observations affirm our previous findings that tonic TNFR1-dependent signaling is sufficient to dictate outcome during MCMV
infection of macrophages [29]. The threshold was not amplified by the addition of extraneous cytokine. Necroptotic RIPK3 [30], pyroptotic mediators (CASP1 and CASP11) [96,97],
pyroptosis executioner gasdermin D [98], MCMV-associated inflammasome components
(adaptor ASC, nucleic acid sensor AIM2) [99], as well type I and type II interferon signaling
(via interferon alpha/beta receptor 1 [IFNAR1] or interferon gamma receptor [IFNGR]
respectively) were all dispensable for the BAX/BAK-dependent death induced by the
vMIA/vIBO-deficient virus (Figures 3D and S3A). The behavior of ∆M36 affirmed previous findings [29] showing that vICA was necessary to suppress TNFR1-dependent cell
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death (Figure 3A). M45mutRHIM-infected WT or Tnfr1−/− cells exhibited similar susceptibility to cell death that remained dependent on necroptosis mediator RIPK3, but not
on RIPK1, CASP8, nucleic acid sensor ZBP1, or BAX and BAK (Figures 3B–D and S3B).
Interestingly, Bax−/− Bak−/− cells exhibited enhanced susceptibility to the M45mutRHIMdependent necroptosis. These observations clearly lay out the key host targets for each
cell death suppression mechanism. M45-encoded vIRA specifically suppresses RIPK3dependent signaling independently of TNF, CASP8, or BAX/BAK; M36-encoded vICA
suppresses TNF-dependent CASP8 activation independently of RIPK3, BAX and BAK;
M38.5/M41.1-encoded vMIA/vIBO specifically suppresses BAX- and BAK-dependent
signaling where TNF appears to contribute to earlier events. Curiously, M45mutRHIMinfected Bax−/− Bak−/− cells exhibited enhancement when compared with WT settings
(Figure S3B), suggesting that even though the mitochondrial pro-death proteins are overall
dispensable, they restrain necroptotic signaling. Thus, in macrophages, MCMV employs
distinct, non-redundant suppression strategies to prevent infection-induced necroptosis,
apoptosis, and mitochondrial cell death. All PCD suppressors are necessary to maintain
viral replication, as well as full pathogenesis in vivo (Figure 1B,C and [30]).
3.5. vMIA and vIBO Interface with vIRA and vICA
To evaluate the temporal aspects of PCD suppression by vIRA, vICA, vMIA and
vIBO, we compared the parental virus to M45mutRHIM (inducer of RIPK3-dependent
necroptosis), ∆M36 (inducer of CASP8-dependent apoptosis), and ∆M38.5/M41.1 viruses
during infection of WT macrophages (Figures 3E and S3C). Cell death was measured by
integration of specific fluorescent signal of cell-impermeable dye Sytox Green as the execution of PCD signaling increases membrane permeability. Neither mock treatment nor K181
infection induced permeability. M45mutRHIM-infected cells exhibited a rapid increase
in cell permeability within 6 to 9 hpi. Necroptosis was evident by 12 hpi (Figures 3E and
S3C, third row). ∆M36 and ∆M38.5/M41.1 mutant viruses revealed comparable timing
of cell death, first becoming evident by 12 to 15 hpi (Figure 3E). ∆M38.5/M41.1-induced
cell death remained overall less prominent compared with that induced by ∆M36 infection (Figure S3C fourth and fifth rows). This relatively slow development of PCD with
vMIA/vIBO double-deficient viruses was expected for infection-triggered mitochondrial
stress as observed with HCMV vMIA mutant or MCMV single mutant disrupting M38.5
or M41.1 expression [13,17,31,36,38]. Therefore, M45mutRHIM-induced necroptosis represents the most robust and immediate form of cell death in MCMV-infected BMDM,
followed by ∆M36-induced extrinsic apoptosis and ∆M38.5/M41.1-induced mitochondrial
cell death. Elaboration of PCD suppression during MCMV infection of macrophages
controls this temporal network. Each suppressor functions independently of the others
with a feed-forward crosstalk between pathways as indicated by the contributions of TNF
to the mitochondrial signaling (Figure 3A,B) or BAX and BAK to necroptotic signaling
(Figure S3B), as well as the role of CASP8 suppression in the induction of necroptosis [30].
3.6. vIRA, vICA, vMIA and vIBO Interface with Innate Inflammation
Cytokines induced during infection synergize with PCD signaling (mitochondrial and
non-mitochondrial) in cells and tissues [75,100,101]. We sought to assess the potential for
communication between PCD pathways, virus-encoded death suppressors, and innate
inflammation. Analysis of cytokine and chemokine release from WT BMDM showed
that infected M45mutRHIM-, ∆M36-, and ∆M38.5/M41.1-infected cells show patterns of
inflammation that are distinct from K181 as well as from each other (Figures 3F and S4).
M45mutRHIM induced ~70% loss of viability (Figure 3B) and a reduction in cytokines and
chemokines except for IL-27 (Figures 3F and S4). ∆M36 induced ~50–60% viability loss
associated with a surprising elevation of several cytokines and chemokines including IL-27,
CXCL-10 (IP-10), CXCL-1 (KC), M-CSF, Mip-1α, and MIP-1β. Several others including
siCAM-1, IL1ra, IL-10, IL-16, and MCP-1 (JE) did not show a noticeable difference from
the K181 infection setting. ∆M36-induced G-CSF, IL-6, MCP-5, MIP-2, RANTES, SDF-1,
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TIMP-1, and TNF were reduced compared with K181. ∆M38.5/M41.1 induced ~30–40%
viability loss but a dramatic reduction in overall cytokines and chemokines. Thus, during
the course of infection, macrophages may support necroptosis with reduced inflammatory
markers, extrinsic apoptosis with elevated inflammatory markers, and activated BAX/BAKdependent signaling with reduced inflammatory markers. From these observations, it
appears that vIRA, vMIA, and vIBO potentiate innate inflammation by restraining the
host factors RIPK3, BAX, and BAK, whereas vICA suppresses inflammation by preventing
CASP8 activation. Overall, concerted functions of vIRA, vICA, vMIA, and vIBO dictate
12 of 25
optimal infection conditions for MCMV by regulating death signaling
and replication, as
well as innate inflammation.
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3.5. vMIA and vIBO Interface with vIRA and vICA
To evaluate the temporal aspects of PCD suppression by vIRA, vICA, vMIA and
vIBO, we compared the parental virus to M45mutRHIM (inducer of RIPK3-dependent
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3.7. Ripoptosome Components Are Dispensable in vMIA/vIBO-Dependent Signaling
To identify crosstalk between extrinsic and intrinsic cell death components during
MCMV infection, we assessed cytosolic death players RIPK1 and CASP8 because of their key
roles in PCD signaling [102–106]. Extracellular or intracellular stress often induces the association of adaptor FADD with RIPK1 and CASP8, leading to the formation a multi-functional,
pro-death platform known as the ripoptosome [106–109]. RIPK1 engagement has been
observed downstream to both extrinsic TNF-dependent and intrinsic BAX/BAK-mediated
signaling [110–112]. MCMV infection engages RIPK1, CASP8, and RIPK3 in BMDM [29,30],
but how these proteins play out in the context of vMIA/vIBO-dependent signaling remains
unresolved. RIPK3 and ZBP1 may contribute to ripoptosome function. We infected WT,
Ripk3−/− , Casp8−/− Ripk3−/− , Ripk1−/− Casp8−/− Ripk3−/− , and Zbp1−/− BMDM, as well as
cells expressing kinase inactive versions of RIPK1 (Ripk1K45A/K45A ) or RIPK3 (Ripk3K50A/K50A )
with K181 or ∆M38.5/M41.1 mutant virus (Figures 4A,B and S5A–C). All genotypes exhibited similar susceptibility to vMIA/vIBO-deficient virus-induced cell death (Figures 4A,B
and S5A) establishing that RIPK1, RIPK3, CASP8, and ZBP1 were completely dispensable
for mitochondrial cell death. Immunoblot analysis of WT, and Ripk1−/− Casp8−/− Ripk3−/−
BMDM infected with K181, M45mutRHIM, ∆M36, or ∆M38.5/M41.1 established activation
patterns of caspase implicated in extrinsic apoptosis (CASP8-CASP3-CASP7) [29] or mitochondrial cell death (CASP9-CASP3-CASP7) [113,114] at 24 hpi (Figure 4C). WT, but not
Ripk1−/− Casp8−/− Ripk3−/− cells infected with K181 or M45mutRHIM, differed from mock
infected cells by a detectable increase in levels of cleaved CASP7 (~19 and 17 kDa). Thus,
MCMV infection activates CASP7 independently of vIRA, vICA, and vMIA/vIBO, but is
dependent on ripoptosome components. However, this activated CASP7 did not result
in the death of WT cells during infection with K181. Infection with ∆M36 resulted in the
expected appearance of cleavage-activated CASP8 (~43 and 18 kDa), CASP7 (17 kDa), and
CASP3 (17 kDa) cleavage products. Activated CASP9 (~39–37 kDa) levels were also detected, indicating that this mitochondrial cell-death-associated caspase was engaged during
∆M36 infection, even though mitochondrial BCL2-family proteins were dispensable for the
death [29]. These data clearly showed that removal of vICA-dependent CASP8 suppression has a cascade impact on activation of multiple caspases beyond CASP8. As expected,
Ripk1−/− Casp8−/− Ripk3−/− cells that remained completely resistant to ∆M36-induced apoptosis [30] resisted the activation of CASP8 and CASP3, but surprisingly continued to exhibit
activation of CASP9 and CASP7. It remains surprising that Ripk1−/− Casp8−/− Ripk3−/− cells
showed full activation of proapoptotic caspases despite the absence of core ripoptosome
components. However, CASP9/CASP7 activation in these cells did not drive death in
the absence of these critical ripoptosome components. With ∆M38.5/M41.1 infection, WT
cells exhibited activation of CASP9, CASP7, and CASP3. CASP8 was activated over K181
but in reduced levels compared to ∆M36, consistent with the requirement for vICA in
CASP8 suppression. Ripk1−/− Casp8−/− Ripk3−/− cells also activated CASP9, CASP7, and
CASP3, but at levels modestly reduced compared with WT cells. Death did not differ
between the genotypes (Figure 4A,B), demonstrating that the lower levels of the CASPactivation pattern expressed in Ripk1−/− Casp8−/− Ripk3−/− cells were sufficient to induce
mitochondria-dependent death signaling. The lower levels of CASP8 activation may reflect
the contribution from TNFR1 (Figure 3B), which is known to signal through RIPK1 and
CASP8 [109]. Therefore, extrinsic death signaling does not impact double mutant-induced
mitochondrial death signaling. vMIA/vIBO double-deficient virus maintained attenuation
in Casp8−/− Ripk3−/− BMDM (Figure S5A–C). In salivary glands from Casp8+/− Ripk3−/−
mice, this attenuation was evident at 14 dpi (Figure S5D). However, in Casp8−/− Ripk3−/−
mice, double-deficient MCMV exhibited a spread in viral titer, indicating TNF-CASP8dependent signaling may amplify the innate immune response to restrict virus infection
in vivo. Therefore, vMIA and vIBO target the mitochondria to prevent cell death and benefit
fitness independently of known extrinsic PCD signaling components and pathways. Other
PCD signaling pathways potentially influence outcomes in vivo.
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4. Discussion
Here, we reveal an intricate interplay between virus-encoded PCD suppressors, mammalian PCD machinery, and TNF-dependent signaling. Cellular pathways may collaborate
to undermine cell viability, cut short virus replication, and drive infection-associated
inflammation in the absence of dedicated MCMV-encoded PCD suppressors. We introduce new concepts regarding the involvement of mitochondria in this infected cell deathinflammation matrix. Mitochondrial HtrA2/Omi restrains MCMV replication, reminiscent
of its role in restricting HCMV infection in fibroblasts via the induction of PCD [13,49].
However, in MCMV-infected BMDM, this serine protease limits infection independently
of PCD. Recently, it has been demonstrated that HCMV vMIA suppresses BAX/BAKdependent signaling to facilitate the infection of mast cells [37]. Future investigations with
HCMV and MCMV in myeloid and non-myeloid lineages will be necessary to resolve
potential differences between HCMV studies and our current observations with MCMV.
Tissue-specific contributions from HtrA2/Omi or differences between the human and
murine viruses might certainly be expected given the ninety million years of evolutionary
divergence in these two biologically similar viruses. Overall, we add MCMV vMIA/vIBO
as a modest suppressor of HtrA2/Omi to the known herpesvirus-encoded suppressors,
HCMV-encoded vMIA [13] and HHV-8-encoded vIRF1 [115]. Studies with MCMV single
mutant for either vMIA or vIBO have established BAX and BAK as specific targets for the
viral suppressors [31,38]. We expanded that understanding by implicating HtrA2/Omi and
TNF-dependent signaling as additional targets. vMIA/vIBO double-deficient MCMV failed
to efficiently express the immediate early viral protein IE1 in macrophages (Figure S1C).
The other cell death suppressor, mutant MCMV generated on this K181-BAC parental background, as well as single mutants for vMIA or vIBO did not show a similar defect [30–32],
indicating vMIA/vIBO may potentially regulate the initial steps controlling entry prior
to immediate early gene expression. Future studies in primary and immortalized murine
cells will be necessary to determine the full scope of contribution by these suppressors
during infection. During infection, vMIA/vIBO suppress an early involvement of TNF
beyond BAX/BAK such that the double-mutant virus drives TNFR1-dependent death
by 24 hpi (Figure 3B). In Casp8−/− Ripk3−/− but not Casp8+/− Ripk3−/− mice, vMIA/vIBO
mutant MCMV exhibited a spread in replication (Figure S5D). TNF signaling showed an
intricate association with both HCMV and MCMV infection [12,13,17,18,29,75,116–118],
although never before implicated in mitochondrial signaling. Our observations indicated
that TNF-dependent signaling augments vMIA/vIBO mutant MCMV-driven death in
macrophages and amplifies response in mice via CASP8 activation.
Surprisingly, TNF-driven death during vMIA/vIBO-deficient mutant infection occurs
independently of CASP8 and despite the presence of virus-encoded vICA. Thus, vICA
successfully restricts the known TNFR1-CASP8 death signaling. TNFR1 plays a role early
in infection, but BAX/BAK activity bypasses any contribution from this cytokine later
in infection. Bax−/− Bak−/− BMDM exhibit a partial rescue from double mutant-induced
death. Elimination of TNFR1-dependent signaling along with BAX/BAK must be evaluated for impact on cellular viability and in vivo replication during double-mutant virus
infection. From the data shown here, it appears that overlapping intrinsic and extrinsic
PCD signaling pathways may converge in the mitochondria late during MCMV infection
where vMIA/vIBO mitigates impacts from both pathways. BAX/BAK-interacting partners
BID, BIM, and PUMA are individually dispensable but contribute together, consistent
with the potential diversity of BAX and BAK activators as infection progresses. Whether
HCMV vMIA elicits a similar suppression strategy against both extrinsic and intrinsic
death signaling will come from future assessment. TNF is known to induce extrinsic
death via cytosolic FADD-RIPK1-CASP8 association [119], with mitochondrial amplification in BID-dependent as well as BID-independent signaling [57,58,120–123]. RIPK1 and
CASP8 are elevated by 14 hpi in infected macrophages [29] and possibly contribute to
the early TNFR1 impact but remain ultimately uninvolved in the pathway suppressed
by vMIA/vIBO. The role of BID, the recognized bridge between TNF and mitochondrial
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amplification [44,57,58,120,122,123], remains unclear. The picture that emerges regarding
vMIA/vIBO suppression seems reminiscent of adenovirus-encoded viral BCL-2 antagonist
E1B 19K, a function that suppresses analogous TNF-mitochondria synergy during infection [124]. There may be a common pattern during DNA virus infections. Our observations
demand future experiments to elucidate how the TNF-mitochondria synergy plays out
in cells as well as in vivo, especially during MCMV pathogenesis settings where TNF
signaling contributes to outcomes [74,75,125].
Even though the host players for extrinsic apoptosis, necroptosis and mitochondrial
death, exhibit limited crosstalk, a remarkable partitioning exists between the pathways
MCMV-encoded PCD suppressors vIRA, vICA, and vMIA/vIBO hold under control.
MCMV has evolved to antagonize amplification of the antiviral response as infection
progresses such that each suppressor functions non-redundantly in particular subcellular
location. Immediately following the infection of macrophages, MCMV faces RIPK3 in
the cytoplasm. vIRA, a tegument-associated protein, is expressed early to usurp RIPK3
RHIM engagement [17,126]. vIRA also disrupt RIPK1, ZBP1, and TRIF RHIM-dependent
signaling [14,72,82]. However, all these players, as well as TNF and types I and II interferons, remain dispensable for vIRA function during MCMV infection of macrophages
(Figures 3A and S3B and [30]). In fibroblasts or endothelial cells, the nucleic acid sensor
ZBP1 initiates this signaling [14,15,30]. Therefore, even though vIRA-dependent RIPK3
suppression is critical for MCMV infection and pathogenesis independent of cell type [30],
the requirements to trigger this signaling in macrophages are less stringent than in nonmyeloid cells. Restricting virus in macrophages may be of critical importance for the
host such that additional requirements beyond RIPK3-MLKL are bypassed. BAX/BAK
surprisingly restrain necroptosis unleashed in the absence of vIRA such that vIRA-deficient
MCMV drives enhanced death in BAX/BAK-deficient cells (Figure S3B). This feedback
loop in combination with our identified TNF-mitochondria crosstalk reveal that extrinsic
apoptosis, necroptosis, and mitochondrial cell death overlap during MCMV infection. The
suppressors function in a non-overlapping fashion to subvert the integrated network of
host PCD pathways. vIRA functions are followed by requirements for vICA in cytoplasm
and vMIA/vIBO in mitochondria as host PCD pathways become activated. Pyroptosis
remains dispensable for all these processes (Figure S3A and [29]). Thus, MCMV subverts
distinct PCD pathways by sequential activation of PCD suppressors that target distinct
PCD pathways in different cellular localizations.
The suppressor-PCD interface during MCMV infection influences innate inflammation
such that by 24 hpi, distinct patterns of cytokine/chemokine release became evident in
the absence cell death suppression (Figures 3F and S4). vIRA-deficient virus exhibited an
overall hypo-inflammatory phenotype. In mice, this mutant virus associates with elevated
innate and adaptive responses [30]. MCMV-infected cells undergoing necroptosis may
be inherently inflammatory by releasing danger signals, but it remains to be determined
whether the balance of signaling undermines viability or protects surrounding cells. Remarkably, vICA-deficient virus infection also exhibited a hyper-inflammatory phenotype.
This could be due to either of two reasons. This apoptotic signal may itself be inflammatory.
By suppressing CASP8, vICA blocks both death-dependent as well as death-independent
inflammation that appear to be unleashed during ∆M36 infection. We previously suggested
this possibility because vICA-deficient virus infection induced higher levels of TNF early
during infection [29]. At the time of assessment (24 hpi), vMIA/vIBO double-deficient
virus infection produced a hypo-inflammatory state, suggesting that unleashed BAX and
BAK reduce the amplification of inflammatory signaling. Thus vMIA/vIBO appear to
be potentiators of inflammation late during MCMV infection, presumably because this
benefits the virus in some way. The consequences of each suppression mechanism on
pathogenesis require further assessment.
In summary, we showed that PCD pathways restrict MCMV infection in macrophages.
Sequential engagement of vIRA, vICA, and vMIA/vIBO, suppressors of RIPK3-dependent
necroptosis, TNFR1-CASP8-dependent apoptosis, and mitochondrial signaling, respec-
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tively, regulate levels of inflammation in cultured macrophages and in vivo. Combined functions of all suppressors establish a protective shield for CMV infection, thereby establishing
these suppressor pathways as potential therapeutic targets during viral pathogenesis. Deactivation of one or more PCD suppressors will restrict virus infection. Elimination of the
mitochondrial suppressors (vMIA/vIBO) reduces viral fitness and overall inflammation.
Given that the functions of these suppressors are conserved between MCMV and HCMV,
we reveal that targeting the mitochondrial suppressors of CMV may be a safe, viable way
to target this virus.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/v13091707/s1, Figure S1: Mutagenesis of M38.5 and M41.1. (A) The genomic integrity of the
K181 and mutant viruses analyzed by electrophoretic separation of EcoRI- and AseI-digested BAC
DNA on 0.6% agarose gels. Arrowheads indicate predicted changes in the EcoRI RFLP pattern of
∆M38.5/M41.1-BAC. A 13 Kbp band generated by EcoRI digestion was disrupted upon insertion of
the 2.9 Kbp Kan/SacB cassette (total size of 15.9 Kbp). The Kan/SacB cassette created an additional
EcoRI restriction site, dividing the 15.9 Kbp fragment into 3.3 Kbp and 12.6 Kbp bands. The loss
of the 13 Kbp band and appearance of the 3.3 Kbp band are marked by the black-and-white arrow
heads. The black only arrowheads indicate the presence of the plasmid pSIM6 encoding the λ red
recombineering functions. pSIM6 digestion by EcoRI and AseI produced a linear 6.7 Kbp band in
the appropriate lanes (lanes 1, 2, and 5). (B,C) Replication kinetics (B) and infectivity (C) of K181 or
∆M38.5/M41.1 virus in WT BMDM at indicated MOIs and times. MCMV-encoded IE1 expression
was used as marker for infectivity. (D,E) replication kinetics of K181 or ∆M38.5/M41.1 in 3T3-SA
(D) and SVEC4-10 (E) cells over the course of time indicated. BMDM were infected at MOI = 0.5,
SVEC4-10 and 3T3-SA cells were infected at MOI = 0.3. Infected cells with media were collected at
1, 3, 5, 7 and 9 dpi. For each panel, data shown are pooled results from at least three experiments
where error bars indicate standard error and mean. Figure S2: M38.5 and M41.1 target BAX and
BAK to facilitate MCMV replication. (A) Immunoblot analysis of cells with transduction settings
described in (A) to detect BAK (~20 kDa) and BAK (~20 kDa) expression with loading control β-actin
(38.5 kDa). Uninfected cells were harvested for immunoblot at the same time infected cells were
collected for titer assessment. (B) Viability of WT, Bid−/− , Bim−/− , Puma−/− and Bok−/− cells infected
with K181 or ∆M38.5/M41.1 (MOI = 10) assessed at 48 hpi. (C–E) Replication of K181, ∆M38.5/M41.1
or M38.5.StopFS/M41.1∆Start viruses in WT and Bid−/− (C), WT, Puma−/− , and Bim−/− BMDM (D),
as well as WT and Bok−/− BMDM (E) at 5 dpi (MOI = 0.05). For each experiment, data shown are
pooled results from at least three experiments. No significant changes in ∆M38.5/M41.1 infection
were observed for any of the mutant cells when compared by Wilcoxon matched-pairs signed rank
test. Error bars indicate standard error and mean for each dataset. Figure S3: Requirements for
mutant MCMV-induced apoptosis and necroptosis. (A) Viability of BMDM from mice of indicated
genotypes infected with K181 or ∆M38.5/M41.1 (MOI = 10) at 48 hpi. Each bar represents the pooled
data from at least three experiments. (B) Viability of BMDM of indicated genotypes infected with
K181 or M45mutRHIM (MOI = 10) at 48 hpi. Each column represents the pooled data from at least
three experiments. Horizontal lines indicate the two groups being compared in each setting utilizing
Wilcoxon matched-pairs signed rank test. Error bars indicate standard error and mean for each
dataset. ** is p < 0.01; *** is p < 0.001; **** is p < 0.0001; n.s. is non-significant. (C) Representative light
microscopy images (lower left scale bar = 200 µM) of WT BMDM infected with indicated viruses at
indicated times. Time stamp from microscope is included in lower right corner of each image. Cell
death is measured by inclusion of cell-impermeable dye (Sytox Green) as cellular membrane loses
integrity due to execution of death signaling. Diffused circular green signal (detected in middle of
lanes of fields without signal from cells) is a nonspecific consequence of the microscope light filter
and camera. Figure S4: Dot blot proteome profiler array of supernatant from infected cells (related to
Figure 3F). Cell-free supernatants from WT BMDM, infected collected 24 hpi with indicated viruses,
were assessed by protein profiler array. A-F represent 6 rows where every two dots are replicates of
distinct proteins. The names of the proteins are reflected in the map provide at lowest panel. Figure S5:
Ripoptosome components are dispensable for ∆M38.5/M41.1 MCMV replication and cell death.
(A) Viability of WT or Ripk3−/− , Ripk3K51A/K51A , Ripk1K45A/K45A , Casp8−/− Ripk3−/− and Zbp1−/−
BMDM infected with K181 or ∆M38.5/M41.1 (MOI = 10) at 48 hpi. Each bar represents pooled
data from at least three experiments. (B) Replication kinetics of K181 or ∆M38.5/M41.1 virus in
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Casp8−/− Ripk3−/− BMDM infected at MOI = 0.5 over 9 days. Replication was measured as described
in Figure S1. (C) Replication of K181 or indicated mutant MCMV in WT or Casp8−/− Ripk3−/− BMDM
infected at MOI = 0.5 for 5 d. For each experiment (A–C), data shown are pooled results from at least
three experiments where error bars indicate standard error and mean for each dataset. (D) Replication
of K181 and ∆M38.5/M41.1 in salivary glands of littermate Casp8+/− Ripk3−/− or Casp8−/− Ripk3−/−
mice at 14 dpi. Mean is indicated for each dataset.
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